Acuta Capital Partners LLC Invests $3.14 Million in Ascendis Pharma A/S (NASDAQ:ASND)

Acuta Capital Partners LLC acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 21,000 shares of the biotechnology company’s stock, valued at approximately $3,136,000. Ascendis Pharma A/S makes up approximately 2.5% of Acuta Capital Partners LLC’s holdings, making the stock its 17th largest position.

A number of other large investors have also added to or reduced their stakes in ASND. Westfield Capital Management Co. LP grew its stake in shares of Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after acquiring an additional 170,942 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Ascendis Pharma A/S by 9.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after purchasing an additional 155,971 shares in the last quarter. Fred Alger Management LLC grew its position in Ascendis Pharma A/S by 65.0% during the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after purchasing an additional 120,952 shares during the last quarter. Finally, Tri Locum Partners LP increased its stake in Ascendis Pharma A/S by 102.1% during the 2nd quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company’s stock valued at $31,062,000 after purchasing an additional 115,092 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Wells Fargo & Company upped their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. TD Cowen cut their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Wedbush restated an “outperform” rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Citigroup increased their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Finally, The Goldman Sachs Group lifted their price objective on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $191.77.

Ascendis Pharma A/S Trading Up 1.3 %

ASND opened at $136.32 on Thursday. The company’s 50 day moving average is $132.80 and its 200 day moving average is $132.18. The company has a market cap of $8.27 billion, a price-to-earnings ratio of -16.58 and a beta of 0.66. Ascendis Pharma A/S has a 12-month low of $90.13 and a 12-month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. As a group, analysts predict that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.